Cargando…

The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis

The aim of this study was to investigate outcomes of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants comprised 164 patients who underwent surgical treatment of spinal metastasis, divided according to whether molecularly targeted therapy was performed. We comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugita, Shurei, Ogiso, Sawako, Fujiwara, Masanori, Morita, Euan, Koyama, Takuma, Hozumi, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299002/
https://www.ncbi.nlm.nih.gov/pubmed/37373615
http://dx.doi.org/10.3390/jcm12123920
_version_ 1785064255665471488
author Sugita, Shurei
Ogiso, Sawako
Fujiwara, Masanori
Morita, Euan
Koyama, Takuma
Hozumi, Takahiro
author_facet Sugita, Shurei
Ogiso, Sawako
Fujiwara, Masanori
Morita, Euan
Koyama, Takuma
Hozumi, Takahiro
author_sort Sugita, Shurei
collection PubMed
description The aim of this study was to investigate outcomes of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants comprised 164 patients who underwent surgical treatment of spinal metastasis, divided according to whether molecularly targeted therapy was performed. We compared survival, local recurrence of metastasis detected by imaging, the disease-free interval, relapses of neurological deterioration, and the ability to walk between groups. Molecularly targeted drugs were administered to 39 patients after surgery (TT group) and were not administered to 125 patients (non-TT group). Median survival was significantly longer in the TT group (1027 days) than in the non-TT group (439 days, p < 0.01). Local recurrence occurred in 25 patients in the non-TT group and 10 patients in the TT group. The disease-free interval did not differ between groups. Neurological deterioration was observed in three patients in the non-TT group and no patients in the TT group. The ability to walk was preserved in 97.6% of patients in the TT group and 88% of patients in the non-TT group (p = 0.12). In conclusion, molecularly targeted drugs improve survival in patients with spinal metastasis but do not alter local control of metastatic tumors.
format Online
Article
Text
id pubmed-10299002
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102990022023-06-28 The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis Sugita, Shurei Ogiso, Sawako Fujiwara, Masanori Morita, Euan Koyama, Takuma Hozumi, Takahiro J Clin Med Brief Report The aim of this study was to investigate outcomes of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants comprised 164 patients who underwent surgical treatment of spinal metastasis, divided according to whether molecularly targeted therapy was performed. We compared survival, local recurrence of metastasis detected by imaging, the disease-free interval, relapses of neurological deterioration, and the ability to walk between groups. Molecularly targeted drugs were administered to 39 patients after surgery (TT group) and were not administered to 125 patients (non-TT group). Median survival was significantly longer in the TT group (1027 days) than in the non-TT group (439 days, p < 0.01). Local recurrence occurred in 25 patients in the non-TT group and 10 patients in the TT group. The disease-free interval did not differ between groups. Neurological deterioration was observed in three patients in the non-TT group and no patients in the TT group. The ability to walk was preserved in 97.6% of patients in the TT group and 88% of patients in the non-TT group (p = 0.12). In conclusion, molecularly targeted drugs improve survival in patients with spinal metastasis but do not alter local control of metastatic tumors. MDPI 2023-06-08 /pmc/articles/PMC10299002/ /pubmed/37373615 http://dx.doi.org/10.3390/jcm12123920 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Sugita, Shurei
Ogiso, Sawako
Fujiwara, Masanori
Morita, Euan
Koyama, Takuma
Hozumi, Takahiro
The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis
title The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis
title_full The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis
title_fullStr The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis
title_full_unstemmed The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis
title_short The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis
title_sort outcome of molecularly targeted therapy after surgical treatment of spinal metastasis
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299002/
https://www.ncbi.nlm.nih.gov/pubmed/37373615
http://dx.doi.org/10.3390/jcm12123920
work_keys_str_mv AT sugitashurei theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT ogisosawako theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT fujiwaramasanori theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT moritaeuan theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT koyamatakuma theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT hozumitakahiro theoutcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT sugitashurei outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT ogisosawako outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT fujiwaramasanori outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT moritaeuan outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT koyamatakuma outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis
AT hozumitakahiro outcomeofmolecularlytargetedtherapyaftersurgicaltreatmentofspinalmetastasis